retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Eli Lilly just announced striking results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Triple Agonism Based Therapies for
Description
doi: 10.1093/cid/civ217
Typically, TNF is involved in systemic inflammation and the acute phase reaction
00967-0/asset/1cda1e69-507e-47d1-ad73-620bcd1cbb66/main.assets/gr2_lrg.jpg)
The authors highlighted the diverse, but significant, ways the 4,000+ patients responded to the medication: 88% of participants lost 5% of body weight or more
Consider taking a multivitamin every day
Gorissen, Stefan H
